•  
  •  
  •  
  •  

2025-12-23 11:19:39

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Aurionpro's Integro Platform to Power Global Lending Modernization for a Top Singaporean Bank
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Puravankara announces acquisition of 53-acre land parcel in Bengaluru with GDV of over Rs 4,800 crores
  • Deccan Gold Mines Ltd to invest in a tungsten project in Spain
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial

Keywords Selected:  INE470Y01017

Stock Report

  • The New India Assurance Company Ltd. Reports all time high Gross Written Premium in FY25 with improved operational metrics
  • New India Assurance reports 128.4% growth in profit after tax in Q 4FY 24
  • New India Assurance reports 15.4% growth in gross written premium and PAT of 715 Cr for Q3FY24
  • The New India Assurance Co Ltd launches Surety Bond Business
  • New India Assurance launches specialised product for the Aviation industry
  • The New India Assurance Company Ltd recommends final dividend of Rs. 0.30
  • Ms. Madhulika Bhaskar appointed as General Manager of The New India Assurance Company Limited
  • The New India Assurance Company Ltd nominates new CIO

Latest Post

  • Aurionpro's Integro Platform to Power Global Lending Modernization for a Top Singaporean Bank
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Puravankara announces acquisition of 53-acre land parcel in Bengaluru with GDV of over Rs 4,800 crores
  • Deccan Gold Mines Ltd to invest in a tungsten project in Spain
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024